The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes

Abstract

Development of antibiotics to treat infections caused by multidrug‐resistant gram‐negative bacilli has lagged significantly behind development of antibiotics to treat infections with gram‐positive pathogens. Although a few promising drugs have entered early clinical development, more must be done to preserve the utility of currently available antibiotics and to ensure a pipeline of efficacious, safe antibacterials.